Sprott Inc’s AMAG Pharmaceuticals AMAG Stock Holding History

Sprott Inc’s Portfolio AMAG Stock Details AMAG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-90,000	Closed	-$2.11M	–	189
2016 Q1	$2.11M	Buy	+90,000	New	+$2.14M	0.17%	90

Other funds holding AMAG

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

SIM

Stelliam Investment Management New York $404M AUM 5.1% 1-Year Est. Return

Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM

Sprott Inc's AMAG Position: Q2 2016 in Review

Sprott Inc sold out of AMAG Pharmaceuticals (AMAG) in Q2 2016, closing a stake of 90,000 shares — an estimated $2.11M sold.

Sprott Inc first reported a position in AMAG in Q1 2016 and held it in 1 quarter. The position peaked at $2.11M in Q1 2016. 165 funds tracked by Wall St. Rank hold AMAG as of Q2 2016.

Sprott Inc reported no remaining AMAG Pharmaceuticals position as of Q2 2016 after selling out during the quarter.
Sprott Inc sold 90,000 AMAG Pharmaceuticals shares in Q2 2016, an estimated $2.11M.
Sprott Inc first reported a position in AMAG Pharmaceuticals in Q1 2016 and held it in 1 quarter.
Sprott Inc's AMAG Pharmaceuticals position peaked at $2.11M in Q1 2016.
165 funds tracked by Wall St. Rank held AMAG Pharmaceuticals as of Q2 2016.

Based on Sprott Inc's 13F filing for Q2 2016, filed 11 Aug 2016.